Sl. No. |
Vaccine type |
Characteristics / Problems |
1. |
Subunit vaccines with adjuvants
(Env epitopes+ MF59) |
Improved but limited antibody response, homologous protection in animal models |
2. |
Subunit vaccines with adjuvants
(Tat/Nef epitopes+ AS01B) |
Improved responses in some of the animal models |
3. |
Subunit gp41 vaccines |
Elicits only mucosal immunity in animal models |
4. |
DNA vaccines |
Elicits mostly CD4+ T-cell response, improved potency ensured by better DNA delivery methods like electroporation. |
5. |
Live recombinant vaccines using vectors |
Mainly elicits CD8+ response and less CD4+ response, immunogenicity hampered in individuals who are pre-immune to vectors, even repeated doses resulted in limited impact.
When used in combination with gp120 proteins, elicits protection in humans. |